Harold J Manley1, Nicole M Allcock. 1. School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri, USA. ManleyH@UMKC.edu
Abstract
STUDY OBJECTIVES: To determine whether thiazolidinediones cause significant changes in intravascular volume, anemia, or chronic heart failure; to determine which thiazolidinedione, rosiglitazone or pioglitazone, has a greater propensity to cause these adverse effects; and to evaluate thiazolidinedione efficacy in patients with diabetes mellitus and end-stage renal disease who require hemodialysis. DESIGN: Retrospective chart review. SETTING: Ambulatory hemodialysis clinic. PATIENTS: Forty ambulatory patients receiving hemodialysis. MEASUREMENTS AND MAIN RESULTS: Of the 40 patients (26 men, 14 women, mean +/- SD age 64.8 +/- 11.5 yrs), diabetes mellitus was the cause of end-stage renal disease in 37 (92.5%). The men were older than the women (mean +/- SD age 67.65 +/- 11.43 yrs and 59.58 +/- 10.6 yrs, respectively, p=0.03). Additional demographic data collected were start date and cause of end-stage renal disease, comorbid conditions, drug profile, hospitalization dates, and reason for admission. Laboratory values were obtained for hematocrit, iron indexes (transferrin saturation and ferritin), mean corpuscular volume, and hemoglobin A1c (A1C); body weight before and after dialysis, and predialysis systolic and diastolic blood pressures were measured. All monitoring parameters were evaluated for 3 months before and after the start of therapy. Three patients were hospitalized for new or worsening chronic heart failure (two were receiving rosiglitazone therapy, one pioglitazone, p=0.555). Changes in A1C values were reviewed to determine thiazolidinedione efficacy; no statistical difference was observed between thiazolidinedione agents prescribed. Combined thiazolidinedione data yielded nonsignificant effects for all clinical and laboratory findings except A1C (-0.61%, p=0.05) and blood pressure (systolic -5.57 +/- 12.09 mm Hg, p=0.01; diastolic -3.24 +/- 6.17 mm Hg, p=0.002). CONCLUSION: Thiazolidinedione therapy is safe and effective for ambulatory patients receiving hemodialysis. However, as we found that these drugs reduced systolic and diastolic blood pressure, further investigation into this drug effect is warranted.
STUDY OBJECTIVES: To determine whether thiazolidinediones cause significant changes in intravascular volume, anemia, or chronic heart failure; to determine which thiazolidinedione, rosiglitazone or pioglitazone, has a greater propensity to cause these adverse effects; and to evaluate thiazolidinedione efficacy in patients with diabetes mellitus and end-stage renal disease who require hemodialysis. DESIGN: Retrospective chart review. SETTING: Ambulatory hemodialysis clinic. PATIENTS: Forty ambulatory patients receiving hemodialysis. MEASUREMENTS AND MAIN RESULTS: Of the 40 patients (26 men, 14 women, mean +/- SD age 64.8 +/- 11.5 yrs), diabetes mellitus was the cause of end-stage renal disease in 37 (92.5%). The men were older than the women (mean +/- SD age 67.65 +/- 11.43 yrs and 59.58 +/- 10.6 yrs, respectively, p=0.03). Additional demographic data collected were start date and cause of end-stage renal disease, comorbid conditions, drug profile, hospitalization dates, and reason for admission. Laboratory values were obtained for hematocrit, iron indexes (transferrin saturation and ferritin), mean corpuscular volume, and hemoglobin A1c (A1C); body weight before and after dialysis, and predialysis systolic and diastolic blood pressures were measured. All monitoring parameters were evaluated for 3 months before and after the start of therapy. Three patients were hospitalized for new or worsening chronic heart failure (two were receiving rosiglitazone therapy, one pioglitazone, p=0.555). Changes in A1C values were reviewed to determine thiazolidinedione efficacy; no statistical difference was observed between thiazolidinedione agents prescribed. Combined thiazolidinedione data yielded nonsignificant effects for all clinical and laboratory findings except A1C (-0.61%, p=0.05) and blood pressure (systolic -5.57 +/- 12.09 mm Hg, p=0.01; diastolic -3.24 +/- 6.17 mm Hg, p=0.002). CONCLUSION:Thiazolidinedione therapy is safe and effective for ambulatory patients receiving hemodialysis. However, as we found that these drugs reduced systolic and diastolic blood pressure, further investigation into this drug effect is warranted.
Authors: Jan Galle; Werner Kleophas; Frank Dellanna; Volkmar H R Schmid; Claudia Forkel; Gerhard Dikta; Vera Krajewski; Winfried Fuchs; Thomas Forst; Andreas Pfützner Journal: Nephron Extra Date: 2012-05-04
Authors: Liana Hakobyan; Flora M Haaijer-Ruskamp; Dick de Zeeuw; Daniela Dobre; Petra Denig Journal: Health Qual Life Outcomes Date: 2011-09-29 Impact factor: 3.186